<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585179</url>
  </required_header>
  <id_info>
    <org_study_id>151/2018</org_study_id>
    <nct_id>NCT03585179</nct_id>
  </id_info>
  <brief_title>Oral and Topical Tranexamic Acid for the Treatment of Melasma</brief_title>
  <acronym>TRANEXAMICO</acronym>
  <official_title>Oral and 5% Topical Tranexamic Acid in Monotherapy Compared With 4% Topical Hydroquinone for the Treatment of Melasma: Three-arm Randomized, Double-blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Dermatológico Dr. Ladislao de la Pascua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Dermatológico Dr. Ladislao de la Pascua</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid has been used for treating melasma due to its effect on decreasing the
      activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy
      and safety of oral and topical tranexamic acid as monotherapy compared with topical
      hydroquinone for 12 weeks in adults with melasma. The primary outcome will be the percentage
      of reduction at 12-week period of mMASI and melanin index. The incidence of adverse effects
      will be reported at weeks 4, 8 and 12.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid has been used for treating melasma due to its effect on decreasing the
      activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy
      and safety of oral and topical tranexamic acid as monotherapy compared with topical
      hydroquinone for 12 weeks in adults with melasma. One hundred and twenty patients will be
      recruited in 3 groups of intervention: group I with tranexamic acid at a dose of 250 mg bid
      orally, group II with 5% topical tranexamic acid bid, group III with 4% topical hydroquinone
      once daily. The primary outcome will be the percentage of reduction at 12-week period of
      mMASI and melanin index. The incidence of adverse effects will be reported at weeks 4, 8 and
      12.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three-arm clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants will receive both topical and oral interventions. Group 1: pills of tranexamic acid 250 mg bid plus placebo gel bid, Group 2: pills of placebo bid plus 5% tranexamic acid gel bid and Group 3: pills of placebo bid plus 4% hydroquinone cream at night and a placebo cream at morning. Containers will be of identical appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mMASI (Modified Melasma Area and Severity Index)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The difference between mMASI (Modified Melasma Area and Severity Index) at week 0 and mMASI (Modified Melasma Area and Severity Index) at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>The reported change of the score of DLQI (Dermatology Life Quality Index) at week 0 versus week 12. Total score ranges from 0 to 30 and the difference between the score at week 0 and week 12 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanin index</measure>
    <time_frame>12 weeks</time_frame>
    <description>The difference between melanin index at week 0 versus week 12. The melanin index will be measure with Mexameter® MX 18. Total index ranges from 0 to 999.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Melasma</condition>
  <condition>Chloasma</condition>
  <condition>Melanosis</condition>
  <arm_group>
    <arm_group_label>Oral tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg of tranexamic acid bid orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5% topical tranexamic acid bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical hydroquinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4% hydroquinone once daily at night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tranexamic Acid</intervention_name>
    <description>Participants will take a pill of 250 mg bid for 12 weeks</description>
    <arm_group_label>Oral tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% topical tranexamic acid</intervention_name>
    <description>Participants will apply a layer of gel on the affected skin bid for 12 weeks</description>
    <arm_group_label>Topical tranexamic acid</arm_group_label>
    <other_name>Topical tranexamic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% hydroquinone</intervention_name>
    <description>Participants will apply a layer of cream on the affected skin once at night</description>
    <arm_group_label>Topical hydroquinone</arm_group_label>
    <other_name>Hydroquinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years

          -  Moderate to severe melasma

          -  History of multiple topical depigmenting treatments and use of photoprotection, with
             subjective improvement less than 50% or mMASI &lt;50% reported by the dermatologist after
             one year of treatment.

        Exclusion Criteria:

          -  Pregnancy

          -  Hormonal contraception

          -  Lactation

          -  Treatment with hydroquinone or tranexamic acid at the time of the study or in the last
             3 months

          -  Endocrinology diseases

          -  Hormone replacement therapy

          -  Family or personal history of one of the following: autoimmune disorders, coagulation
             disorders, chronic venous insufficiency, heart diseases, retinopathies, kidney
             disorders

          -  Mental disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha A Morales-Sánchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Dermatológico Dr. Ladislao de la Pascua</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha A Morales-Sánchez, MD</last_name>
    <phone>55387033</phone>
    <phone_ext>312</phone_ext>
    <email>mmoraless@sersalud.df.gob.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Dermatológico &quot;Dr. Ladislao de la Pascua&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06780</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melasma</keyword>
  <keyword>Chloasma</keyword>
  <keyword>Melanosis</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Hydroquinone</keyword>
  <keyword>Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Hydroquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only if researchers ask for the complete data of the trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

